Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.

AUTOR(ES)

Ratnoff, O D

RESUMO

To investigate the earliest steps of the intrinsic clotting pathway, Hageman factor (Factor XII) was exposed to Sephadex gels to which ellagic acid had been adsorbed; Hageman factor was then separated from the gels and studied in the fluid phase. Sephadex-ellagic acid-exposed Hageman factor, whether purified or in plasma, activated plasma thromboplastin antecedent, but only when high molecular weight kininogen was presnet. In the absence of plasma prekallikrein, maximal activation of plasma thromboplastin antecedent was slightly delayed in plasma, a delay not observed with similarly treated purified Hageman factor. Thus, high molecular weight kininogen was needed for expression of Hageman factor's clot-promoting properties and plasma prekallikrein played a minor role in the interaction of ellagic acid-treated Hageman factor and plasma thromboplastin antecedent.

Documentos Relacionados

• Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.
• The Binding and Cleavage Characteristics of Human Hageman Factor during Contact Activation: A COMPARISON OF NORMAL PLASMA WITH PLASMAS DEFICIENT IN FACTOR XI, PREKALLIKREIN, OR HIGH MOLECULAR WEIGHT KININOGEN
• Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.
• Function and Immunochemistry of Prekallikrein-High Molecular Weight Kininogen Complex in Plasma
• Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma.